Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: The role of ubiquitin proteasome system and therapeutic opportunities

Clinical and Translational Oncology

Volumn 14, Issue 4, 2012, Pages 243-253

  Voutsadakis, Ioannis A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Endometrial carcinosarcoma; Epithelial to mesenchymal transition; Malignant mixed mesodermal tumours; Malignant mixed M llerian tumours; Ubiquitin proteasome system

Indexed keywords

BETA CATENIN; BORTEZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE H2B; MICRORNA; MICRORNA 200C; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; ZINC FINGER PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CARCINOSARCOMA; CELL ADHESION; CELL JUNCTION; CELL PROLIFERATION; CELL TRANSFORMATION; DNA DAMAGE; DRUG RESISTANCE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EPITHELIAL ENDOMETRIAL CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALIGNANT MIXED MULLERIAN TUMOR; MALIGNANT TRANSFORMATION; METAPLASIA; METASTASIS; MIXED MULLERIAN TUMOR; NONHODGKIN LYMPHOMA; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN SUBUNIT; REVIEW; STEM CELL; UBIQUITINATION; UTERUS TUMOR;

BETA CATENIN; CARCINOMA; CELL ADHESION; CYTOPLASM; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESODERM; MODELS, BIOLOGICAL; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 84860775851     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0792-4     Document Type: Review

References (128)

1. El-Nashar SA, Mariani A (2011) Uterine carcinosarcoma. Clin Obstet Gynecol 54:292-304
2. Choijamts B, Jimi S, Kondo T et al (2011) CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor). Stem Cells 29:1485-1495
3. Mani SA, Guo W, Liao M-J et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715 (Pubitemid 351636299)
4. D'Angelo E, Prat J (2011) Pathology of mixed Müllerian tumours. Best Practice Res Clin Obstet Gynaecol 25:705-718
5. McCluggage WG (2002) Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 55:321-325 (Pubitemid 34494168)
6. Sreenan JJ, Hart WR (1995) Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 19:666-674
7. Gorai I, Yanagibashi T, Taki A et al (1997) Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer 72:821-827 (Pubitemid 27431526)
8. Emoto M, Iwasaki H, Kikuchi M, Shirakawa K (1993) Characteristics of cloned cells of mixed Müllerian tumor of the human uterus. Cancer 71: 3065-3075
9. Lien HC, Lin CW, Mao TL et al (2004) p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J Pathol 204:131-139
10. Van Deurzen CHM, Lee AHS, Gill MS et al (2011) Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation? J Pathol 224:434-437
11. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428
12. Stewart CJR, Little L (2009) Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 55:91-101
13. Murray SK, Young RH, Scully RE (2003) Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinomas: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 22:324-333 (Pubitemid 37152980)
14. Stewart CJR, Crook ML, Little L, Louwen K (2011) Correlation between invasive pattern and immunophenotypic alterations in endocervical adenocarcinoma. Histopathology 58:720-728
15. Götte M (2010) Endometrial cells get sidetracked. Side population cells promote epithelialmesenchymal transition in endometrial carcinoma. Am J Pathol 176:25-28
16. Zhou S, Schuetz SD, Bunting KD et al (2001) The ABC transporter Brcp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028-1034 (Pubitemid 32937383)
17. Kato K, Takao T, Kuboyama A et al (2010) Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage. Am J Pathol 176:381-392
18. Leblanc M, Poncelet C, Soriano D et al (2001) Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Arch 438:78-85 (Pubitemid 32128193)
19. Montserrat N, Mozos A, Llobet D et al (2011) Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum Pathol doi: 10.1016/j.humpath.2011.06.021
20. Voutsadakis IA (2010) Ubiquitin, ubiquitination and the ubiquitin-proteasome system in cancer. Atlas Genet Cytogen Oncol Haematol. January. www.AtlasGeneticsOncology.org/Deep/UbiquitinCancerID20083.html
21. Kirkin V, Dikic I (2011) Ubiquitin networks in cancer. Curr Opin Genet Dev 21:21-28
22. Behrends C, Harper JW (2011) Constructing and decoding unconventional ubiquitin chains. Nat Struct Mol Biol 18:520-528
23. van Wijk SJL, Timmers HTM (2010) The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J 24:981-993
24. Amerik AY, Hochstrasser M (2004) Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 1695:189-207 (Pubitemid 39574973)
25. Voutsadakis IA (2007) Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med 11:252-285 (Pubitemid 46695694)
26. Soond SM, Chantry A (2011) How ubiquitination regulates the TGF-ß signaling pathway: new insights and new players. Bioessays 33:749-758
27. Okuda T, Sekizawa A, Purwosunu Y et al (2010) Genetics of endometrial cancers. Obstet Gynecol Int, article id 984013
28. Voss MA, Ganesan R, Ludeman L et al (2012) Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer: a clinical and pathological evaluation. Gynecol Oncol 124:15-20
29. Lax SF (2007) Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 39:46-54
30. Saegusa M, Hashimura M, Kuwata T, Okayasu I (2009) Requirement of the akt/ß-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of Slug. Am J Pathol 174:2107-2115
31. Schipf A, Mayr D, Kirchner T, Diebold J (2008) Molecular genetic aberrations of ovarian and uterine carcinosarcomas: a CGH and FISH study. Virchows Arch 452:259-268
32. Chiyoda T, Tsuda H, Tanaka H et al (2012) Expression profiles of carcinosarcoma of the uterine corpus: are these similar to carcinoma or sarcoma? Genes Chrom Cancer 51:229-239
33. Ng SS, Mahmoudi T, Danenberg E et al (2009) Phosphatidylinositol 3-kinase signaling does not activate the Wnt cascade. J Biol Chem 284:35308-35313
34. Saegusa M, Hashimura M, Kuwata T et al (2007) Crosstalk between NF-?B/p65 and ß-catenin/ TCF4/p300 signalling pathways through alterations in GSK-3ß expression during trans-differentiation of endometrial carcinoma cells. J Pathol 213:35-45 (Pubitemid 47354564)
35. Dai C, Gu W (2010) p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 16:528-536
36. Solomon H, Madar S, Rotter V (2011) Mutant p53 gain of function is interwoven into the hallmarks of cancer. J Pathol 225:475-478
37. Chang CJ, Chao CH, Xia W et al (2011) p53 regulates epithelial- mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13:317-323
38. Wang S-P, Wang W-L, Chang Y-L et al (2009) p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nature Cell Biol 11:694-704
39. Liu M, Casimiro MC, Wang C et al (2009) p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A 106:19035-19039
40. Zhang Y, Yan W, Chen X (2011) Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J Biol Chem 286:16218-16228
41. Kogan-Sakin I, Tabach Y, Buganim Y et al (2011) Mutant p53R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Diff 18:271-281
42. Ohashi S, Natsuizaka M, Wong GS et al (2010) Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res 70: 4174-4184
43. Leng RP, Lin Y, Ma W et al (2003) Pirh2, a p53induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112:779-791 (Pubitemid 36378882)
44. Dornan D, Wertz I, Shimizu H et al (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429:86-92 (Pubitemid 38620556)
45. Chen D, Kon N, Li M et al (2005) ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121:1071-1083 (Pubitemid 40884397)
46. Esser C, Scheffner M, Hohfeld J (2005) The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 280:27443-27448 (Pubitemid 41040787)
47. Buza N, Tavassoli FA (2009) Comparative analysis of p16 and p53 expression in uterine malignant mixed Mullerian tumors. Int J Gynecol Pathol 28:514-521
48. Taylor NP, Zighelboim I, Huettner PC et al (2006) DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 19:1333-1338 (Pubitemid 44423080)
49. Lee S-J, Kim HS, Kim HS et al (2007) Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas. Hum Pathol 38:1226-1231 (Pubitemid 47058160)
50. Kanthan R, Senger J-LB, Diudea D (2010) Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins. World J Surg Oncol 8:60
51. Keeling L, Taraporewalla D, Perunovic B, Smith JHF (2011) Uterine carcinosarcoma with p53positive intraepithelial component. Histopathology 59:1277-1278
52. Cowling VH, Cole MD (2006) Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol 16:242-252 (Pubitemid 44311041)
53. Saegusa M, Hashimura M, Kuwata T et al (2004) ß-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am J Pathol 164: 1739-1749 (Pubitemid 38529776)
54. Yada M, Hatakeyama S, Kamura T et al (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23:2116-2125 (Pubitemid 38737738)
55. Amati B (2004) Myc degradation: dancing with ubiquitin ligases. Proc Natl Acad Sci U S A 101: 8843-8844 (Pubitemid 38781572)
56. Yeh P-Y, Lu Y-S, Ou D-L, Cheng A-L (2011) IκB kinases increase Myc protein stability and enhance progression of breast cancer cells. Mol Cancer 10:53
57. Trimboli AJ, Fukino K, de Bruin A et al (2008) Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68:937-945 (Pubitemid 351206773)
58. Cho KB, Cho MK, Lee WY, Kang KW (2010) Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett 293:230-239
59. Ma L, Young J, Prabhala H et al (2010) miR-9, a MYC/MYCN-activated microRNA, regulates Ecadherin and cancer metastasis. Nature Cell Biol 12:247-256
60. Myatt SS, Wang J, Monteiro LJ et al (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70:367-377
61. Khew-Goodall Y, Goodall GJ (2010) Myc-modulated miR-9 makes more metastases. Nature Cell Biol 12:209-211
62. Weihua Z, Saji S, Mäkinen S et al (2000) Estrogen receptor (ER) ß, a modulator of ER? in the uterus. Proc Natl Acad Sci U S A 97:5936-5941
63. Harris HA (2007) Estrogen receptor-ß: recent lessons from in vivo studies. Mol Endocrinol 21:1-13 (Pubitemid 46041687)
64. Huang GS, Arend RC, Li M et al (2009) Tissue microarray analysis of hormonal signalling pathways in uterine carcinosarcoma. Am J Obstet Gynecol 200:457.e1-457.e5
65. Shabani N, Mylonas I, Jeschke U et al (2007) Expression of estrogen receptors ? and ß, and progesterone receptors A and B in human mucinous carcinoma of the endometrium. Anticancer Res 27:2027-2034
66. Wu W, Slomovitz BM, Celestino J et al (2003) Coordinate expression of cdc25B and ER-? is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res 63:6195-6199 (Pubitemid 37255163)
67. Nilsson S, Koehler KF, Gustafsson J-Å (2011) Development of subtype-elective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 10: 778-792
68. Collins F, MacPherson S, Brown P et al (2009) Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha. BMC Cancer 16:330
69. Chen Y-J, Li H-Y, Huang C-H et al (2010) Oestrogen-induced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis. J Pathol 222:261-270
70. Ito I, Hanyu A, Wayama M et al (2010) Estrogen inhibits transforming growth factor ß signalling by promoting Smad2/3 degradation. J Biol Chem 285:14747-14755
71. Ren Y, Wu L, Frost AR et al (2009) Dual effects of TGF-ß on ER?-mediated estrogenic transcriptional activity in breast cancer. Mol Cancer 8:111
72. Lei XF, Wang L, Yang J, Sun L-Z (2009) TGFß signaling supports survival and metastasis of endometrial cancer cells. Cancer Manag Res 1:15-24
73. Massagué J (2008) TGFß in cancer. Cell 134:215-230
74. Vincent T, Neve EPA, Johnson JR et al (2009) A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-ß mediated epithelial-mesenchymal transition. Nat Cell Biol 11:943-950
75. Huang GS, Gunter MJ, Arend RC et al (2010) Co-expression of GPR30 and ERß and their association with disease progression in uterine carcinosarcoma. Am J Obstet Gynecol 203:242.e1-5
76. Smith HO, Leslie KK, Singh M et al (2007) GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 196: 386.e1-386.e11
77. Wang D, Hu L, Zhang G et al (2010) G proteincoupled receptor 30 in tumor development. Endocrine 38:29-37
78. Vivacqua A, Romeo E, De Marco P et al (2011) GPER mediates the Egr-1 expression induced by 17ß-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Res Treat DOI 10.1007/s10549-011-1901-8
79. Kleuser B, Malek D, Gust R et al (2008) 17-ßEstradiol inhibits transforming growth factor-ß signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30 Mol Pharmacol 74:1533-1543
80. Pandey DP, Lappano R, Albanito L et al (2009) Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28:523-532
81. Ignatov A, Ignatov T, Weißenborn C et al (2011) G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 128:457-466
82. He Y-Y, Cai B, Yang Y-X et al (2009) Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci 100:1051-1061
83. Leung F, Terzibachian J-J, Govyadovskiy A et al (2009) Tamoxifen in the adjuvant setting for breast cancer: reflections about the risk of uterine carcinosarcoma. Gyn Obstet Fertil 37:447-451
84. Fan M, Nakshatri H, Nephew KP (2004) Inhibiting proteasomal proteolysis sustains estrogen receptor-flactivation. Mol Endocrinol 18:2603-2615 (Pubitemid 39482052)
85. Prenzel T, Begus-Nahrmann Y, Kramer F et al (2011) Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasomedependent monoubiquitination of histone H2B. Cancer Res 71:5739-5753
86. StanišiflV, Malovannaya A, Qin J et al (2009) OTU domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER)fland affects ERfltranscriptional activity. J Biol Chem 284:16135-16145
87. Hislop JN, von Zastrow M (2011) Role of ubiquitination in endocytic trafficking of G-proteincoupled receptors. Traffic 12:137-148
88. Cheng S-B, Quinn JA, Graeber CT, Filardo EJ (2011) Down-modulation of the G-protein-coupled Estrogen Receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway. J Biol Chem 286:22441-22455
89. Inoue Y, Imamura T (2008) Regulation of TGF-ß family signaling by E3 ubiquitin ligases. Cancer Sci 99:2107-2112
90. Lin X, Liang M, Feng XH (2000) Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 275: 36818-36822 (Pubitemid 32002092)
91. Bengoechea-Alonso MT, Ericsson J (2010) Tumor suppressor Fbw7 regulates TGFß signaling by targeting TGIF1 for degradation. Oncogene 29: 5322-5328
92. Wan M, Tang Y, Tytler EM et al (2004) Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1. J Biol Chem 279:14484-14487 (Pubitemid 38618834)
93. Hurt EM, Saykally JN, Anose BM et al (2008) Expression of the ZEB1 (?EF1) transcription factor in human: additional insights. Mol Cell Biochem 318:89-99
94. Spoelstra NS, Manning NG, Higashi Y et al (2006) The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 66:3893-3902
95. Singh M, Spoelstra NS, Jean A et al (2008) ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 21:912-923 (Pubitemid 351896667)
96. Kyo S, Sakaguchi J, Ohno S et al (2006) High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol 37:431-438
97. Tsukamoto H, Shibata K, Kajiyama H et al (2007) Irradiation-induced epithelial-mesenchymal transition (EMT) related to invasive potential in endometrial carcinoma cells. Gynecol Oncol 107:500-504 (Pubitemid 350160864)
98. Yoshida H, Broaddus R, Cheng W et al (2006) Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition. Cancer Res 66:889-897 (Pubitemid 43165955)
99. Blechschmidt K, Kremmer E, Hollweck R et al (2007) The E-cadherin repressor Snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol 16:222-228 (Pubitemid 350196980)
100. Castilla MÁ, Moreno-Bueno G, Romero-Pérez L et al (2010) Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 223:72-80
101. Huszar M, Pfeifer M, Schirmer U et al (2010) Upregulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 220:551-561
102. Howe EN, Cochrane DR, Richer JK (2011) Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 13:R45
103. Dong P, Kaneuchi M, Watari H et al (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10:99
104. Lander R, Nordin K, LaBonne C (2011) The F-box protein Ppa is a common regulator of core EMT factors Twist, Snail, Slug, and Sip1. J Cell Biol 194:17-25
105. Vernon AE, LaBonne C (2006) Slug stability is dynamically regulated during neural crest development by the F-box protein Ppa. Development 133:3359-3370 (Pubitemid 44501838)
106. Viñas-Castells R, Beltran M, Valls G et al (2010) The hypoxia-controlled FBXL14 ubiquitin ligase targets SNAIL1 for proteasome degradation. J Biol Chem 285:3794-3805
107. Harris TJC, Tepass U (2010) Adherens junctions: from molecules to morphogenesis. Nat Rev Mol Cell Biol 11:502-514
108. Meng W, Takeichi M (2009) Adherens junction: molecular architecture and regulation. Cold Spring Harb Perspect Biol 1:a002899
109. Fujita Y, Krause G, Scheffner M et al (2002) Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 4:222-231 (Pubitemid 34218196)
110. Rodríguez-Rigueiro T, Valladares-Ayerbes M, Haz-Conde M et al (2011) Hakai reduces cellsubstratum adhesion and increases epithelial cell invasion. BMC Cancer 11:474
111. Shih H-C, Shiozawa T, Miyamoto T et al (2004) Immunohistochemical expression of E-cadherin and ß-catenin in the normal and malignant human endometrium: an inverse correlation between Ecadherin and nuclear ß-catenin expression. Anticancer Res 24:3843-3850 (Pubitemid 40468674)
112. Nishimura I, Ohishi Y, Oda Y et al (2011) Expression and localization of E-cadherin and ßcatenin in uterine carcinosarcoma. Virchows Arch 458:85-94
113. Stefansson IM, Salvesen HB, Akslen LA (2004) Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 22:1242-1252 (Pubitemid 41079838)
114. Mannelqvist M, Stefansson IM, Bredholt G et al (2011) Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol 178:861-871
115. Tanimoto H, Shigemasa K, Sasaki M et al (2000) Differential expression of matrix metalloprotease-7 in each component of uterine carcinosarcoma. Oncol Rep 7:1209-1212
116. Haga A, Funasaka T, Deyashiki Y, Raz A (2008) Autocrine motility factor stimulates the invasiveness of malignant cells as well as up-regulation of matrix metalloproteinase-3 expression via a MAPK pathway. FEBS Lett 582:1877-1882
117. Hirota Y, Osuga Y, Hirata T et al (2005) Evidence for the presence of protease-activated receptor 2 and its possible implication in remodeling of human endometrium. J Clin Endocrinol Metab 90:1662-1669 (Pubitemid 40464035)
118. Tobinai K (2007) Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol 12:318-326 (Pubitemid 47573415)
119. Jain S, Diefenbach C, Zain J, O'Connor OA (2011) Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evidence 6:43-57
120. Driscoll JJ, DeChowdhury R (2010) Therapeutically targeting the SUMOylation, ubiquitination and proteasome pathways as a novel anticancer strategy. Targ Oncol 5:281-289
121. D'Arcy P, Brnjic S, Hägg Olofsson M et al (2011) Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 17:1636-1640
122. Zhao M, Vuori K (2011) The docking protein p130Cas regulates cell sensitivity to proteasome inhibition. BMC Biol 9:73
123. Voutsadakis IA (2011) Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 3:153-164
124. Wang M, Medeiros BC, Erba HP et al (2011) Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin Ther Targets 15:253-264
125. Liu G, Xirodimas DP (2010) NUB1 promotes cytoplasmic localization of p53 through cooperation of the NEDD8 and ubiquitin pathways. Oncogene 29:2252-2261
126. Broemer M, Tenev T, Rigbolt KTG et al (2010) Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases. Mol Cell 40:810-822
127. Dickens MP, Fitzgerald R, Fischer PM (2010) Small-molecule inhibitors of MDM2 as a new anticancer therapeutics. Semin Cancer Biol 20:10-18
128. Zhuang C, Miao Z, Zhu L et al (2011) Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53MDM2 protein-protein interaction. Eur J Med Chem 46:5654-5661